Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Phase 1

Completed

Conditions: Neuroblastoma

Interventions: Biological: beta-glucan
Biological: monoclonal antibody 3F8
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

First Posted Date: 2007-06-27

Last Posted Date: 2022-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT00492167

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer
Metastatic Cancer

Interventions: Drug: dexamethasone
Drug: floxuridine
Drug: irinotecan hydrochloride
Drug: fluorouracil
Drug: oxaliplatin
Drug: leucovorin calcium

First Posted Date: 2007-06-27

Last Posted Date: 2024-05-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT00492999

Locations: 🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States

and more 1 locations

Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners

Not Applicable

Completed

Conditions: Psychosocial Effects of Cancer and Its Treatment
Sexual Dysfunction
Prostate Cancer
Sexuality and Reproductive Issues

Interventions: Other: counseling intervention
Other: questionnaire administration
Procedure: psychosocial assessment and care

First Posted Date: 2007-06-07

Last Posted Date: 2018-03-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT00483678

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Fox Chase Cancer Center - Cheltenham, Philadelphia, Pennsylvania, United States

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: lapatinib ditosylate
Drug: paclitaxel
Other: laboratory biomarker analysis

First Posted Date: 2007-06-05

Last Posted Date: 2017-05-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 95

Registration Number: NCT00482391

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Phase 2

Completed

Conditions: Desmoid Tumor
Endometrial Cancer
Adult Malignant Fibrous Histiocytoma of Bone
Ovarian Cancer
Sarcoma
Small Intestine Cancer

Interventions: Drug: sunitinib malate

First Posted Date: 2007-05-17

Last Posted Date: 2016-01-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 53

Registration Number: NCT00474994

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: counseling intervention
Behavioral: questionnaire administration
Behavioral: psychosocial assessment and care
Behavioral: quality-of-life assessment

First Posted Date: 2007-05-10

Last Posted Date: 2024-01-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 357

Registration Number: NCT00471601

Locations: 🇬🇧
University College of London Hospitals, London, England, United Kingdom
🇺🇸
New School for Social Research, New York, New York, United States
🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 1 locations

Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma

Phase 1

Completed

Conditions: Neuroblastoma

Interventions: Drug: ethanol

First Posted Date: 2007-05-10

Last Posted Date: 2013-03-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT00471679

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Biological: QS21
Biological: sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine
Other: immunoenzyme technique
Other: immunologic technique
Other: laboratory biomarker analysis

First Posted Date: 2007-05-07

Last Posted Date: 2020-11-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT00470574

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Extragonadal Germ Cell Tumor
Ovarian Cancer
Teratoma
Testicular Germ Cell Tumor

Interventions: Biological: pegfilgrastim
Drug: cisplatin
Drug: ifosfamide
Drug: paclitaxel

First Posted Date: 2007-05-07

Last Posted Date: 2017-11-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT00470366

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: Bevacizumab

First Posted Date: 2007-05-03

Last Posted Date: 2016-01-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 62

Registration Number: NCT00468585

Locations: 🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy